SouthernSun Asset Management, LLC, an investment management firm, released its “SouthernSun Small Cap Strategy” third quarter ...

Analyst Michael Petusky of Barrington maintained a Buy rating on US Physical Therapy (USPH – Research Report), retaining the price target ...

Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted ...

Compass Pathways is advancing pivotal trials to test psilocybin's impact on treatment-resistant depression. See why I rate ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Ocugen (OCGN – Research Report). The associated price ...

Click here for a full investment analysis of Cybin Inc., a speculative play on FDA approval for psychedelic-based treatments.

The stock looks increasingly attractive ... Madrigal Pharmaceuticals, a company that earned approval for the first therapy for metabolic dysfunction-associated steatohepatitis (MASH), has no ...

Two Australian brands took great advantage of one of the year's biggest retail events to get noticed on the world stage.

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Welcome to Natera’s 2024 Third Quarter Financial Results ...

MaxCyte now expects full year 2024 core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year ...

Q3 2024 Earnings Call Transcript October 30, 2024Day One Biopharmaceuticals, Inc. beats earnings expectations.